Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)

NCT02972658 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02972658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02972658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
March 15, 2017
Completion date
October 2, 2018
Enrollment
421 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease